Jefferies Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Jefferies has initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and set a price target of $35.

July 02, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has initiated coverage on Rapport Therapeutics with a Buy rating and set a price target of $35.
The initiation of coverage with a Buy rating and a specific price target of $35 by a reputable analyst from Jefferies is likely to positively influence investor sentiment and drive short-term price appreciation for Rapport Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100